4-way competition in NOAC market, well-played by Eliquis and Lixiana

Published: 2017-08-17 16:29:00
Updated: 2017-08-17 14:15:44

While 4 products are settled in the novel oral anticoagulant(NOAC) market, competition is expected to get fiercer.

Bayer’s Xarelto(rivaroxaban) gained the summit of the market; BMS’s Eliquis(apixaban) and a new strong competitor Daiichi Sankyo’s Lixiana(edoxaban) continued a growth; Boehringer I...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.